Breaking barriers: Intranasal delivery of brexpiprazole-nanostructured lipid carriers targets the brain for effective schizophrenia treatment

• NLCs offer improved drug stability, bioavailability and site-specific targeting to the brain upon intranasal administration. • BXP-NLCs administered through intransal route targets brain and is a non invasive delivery. • This research suggests that BXP-NLCs have the potential to be a promising drug delivery for the treatment of Schizophrenia.